Comparison · NCT04331795-fb5cf9ac
Group A vs Group B: Number of Participants With Clinical Response in Maximum Temperature (Tmax)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A vs Group B: Number of Participants With Clinical Response in Maximum Temperature (Tmax). Trial comparisons, record NCT04331795-fb5cf9ac. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04331795-fb5cf9ac
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.667 | 0.391 | 0.862 | wilson | |
| Risk in group 2 | 0.8 | 0.584 | 0.919 | wilson | |
| Risk difference, group 1 minus group 2 | -0.133 | -0.434 | 0.158 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.833 | 0.528 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 0.5 | 0.0984 | 2.54 | log | |
| Number needed to treat, for one fewer participant with the outcome on Group A than on Group B | 7.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A | Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation~Tocilizumab: Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L | 8 | 12 | OG000 |
| Group 2 | Group B | Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation~Tocilizumab: Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L | 16 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Clinical Response in Maximum Temperature (Tmax)
- Description
- Number of Participants with Clinical Response in Maximum Temperature (Tmax)
- Time frame
- Assessed for the 24 hour period after tocilizumab administration
- Population
Source ClinicalTrials.gov
Trial
- Title
- Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
- NCT number
- NCT04331795
- Phases
- PHASE2
- Conditions
- COVID-19
- Interventions
- Tocilizumab, Tocilizumab
- Lead sponsor
- University of Chicago
- Results first posted
- 2022-06-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04331795?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04331795-fb5cf9ac